Literature DB >> 25852296

Treatment of Crohn's disease and familial Mediterranean fever by leukopheresis: single shot for two targets.

Mahmut Yuksel1, Fatih Saygili1, Orhan Coskun1, Nuretdin Suna1, Mustafa Kaplan1, Ufuk Baris Kuzu1, Zeki Mesut Yalin Kilic1, Yasemin Ozderin Ozin1, Ertugrul Kayacetin1.   

Abstract

Coexistence of Crohn's disease (CD) and familial Mediterranean fever (FMF) is a rare condition and knowledge about this clinical situation is limited with a few case reports in the literature. The treatment of both diseases depends on their individual therapies. However, it is very hard to deal with this coexistence when CD is refractory to standard therapies. Ongoing activity of CD triggers the clinical attacks of FMF and the symptoms like abdominal pain interfere with both disease presentations which can cause problems about diagnostic and therapeutic approach. The main therapeutic agent for FMF is colchicine and diarrhea is the most common side effect of this drug. This side effect also causes problems about management of these diseases when both of them are clinically active. Here we report probably the first case in the literature with coexisting CD and FMF who was successfully treated by leukopheresis since he was refractory to conventional therapies for CD.

Entities:  

Keywords:  Crohn’s disease; Familial Mediterranean fever; Leukopheresis

Mesh:

Substances:

Year:  2015        PMID: 25852296      PMCID: PMC4385558          DOI: 10.3748/wjg.v21.i13.4078

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  11 in total

Review 1.  Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes.

Authors:  Abby R Saniabadi; Hiroyuki Hanai; Ken Takeuchi; Kazuo Umemura; Mitsuyoshi Nakashima; Taro Adachi; Chikako Shima; Ingvar Bjarnason; Robert Lofberg
Journal:  Ther Apher Dial       Date:  2003-02       Impact factor: 1.762

2.  The familial Mediterranean fever (MEVF) gene as a modifier of Crohn's disease.

Authors:  Herma Fidder; Yehuda Chowers; Zvi Ackerman; Rivka Dresner Pollak; J Bart A Crusius; Avi Livneh; Simon Bar-Meir; Benjamin Avidan; Yael Shinhar
Journal:  Am J Gastroenterol       Date:  2005-02       Impact factor: 10.864

Review 3.  Selective leukocyte apheresis for the treatment of inflammatory bowel disease.

Authors:  Maria T Abreu; Scott Plevy; Bruce E Sands; Robert Weinstein
Journal:  J Clin Gastroenterol       Date:  2007 Nov-Dec       Impact factor: 3.062

Review 4.  Leukocytapheresis in the treatment of inflammatory bowel disease: Current position and perspectives.

Authors:  Piero Vernia; Valeria D'Ovidio; Donatella Meo
Journal:  Transfus Apher Sci       Date:  2010-10       Impact factor: 1.764

5.  Selective depletion of peripheral granulocyte/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohn's disease.

Authors:  Ken Fukunaga; Yoko Yokoyama; Koji Kamikozuru; Koji Yoshida; Risa Kikuyama; Kazuko Nagase; Shiro Nakamura; Yoshiyuki Takei; Hiroto Miwa; Takayuki Matsumoto
Journal:  J Clin Apher       Date:  2010       Impact factor: 2.821

6.  Treatment of refractory Crohn's disease by intensive granulocyte and monocyte adsorption apheresis: a report on two drug refractory cases.

Authors:  Shingo Kato; Kazuhito Kani; Hidehiko Takabayashi; Ryuichi Yamamoto; Tomonari Ogawa; Akihiko Matsuda; Koji Yakabi
Journal:  Intern Med       Date:  2011-08-01       Impact factor: 1.271

7.  Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study.

Authors:  Yoshihiro Fukuda; Toshiyuki Matsui; Yasuo Suzuki; Kazunari Kanke; Takayuki Matsumoto; Masakazu Takazoe; Takayuki Matsumoto; Satoshi Motoya; Terasu Honma; Koji Sawada; Tsuneyoshi Yao; Takashi Shimoyama; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2004-12       Impact factor: 7.527

Review 8.  Leukocytapheresis for the treatment of IBD.

Authors:  Fridrik Thor Sigurbjörnsson; Ingvar Bjarnason
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-07-29

9.  An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment.

Authors:  Atsushi Sakuraba; Satoshi Motoya; Kenji Watanabe; Masakazu Nishishita; Kazunari Kanke; Toshiyuki Matsui; Yasuo Suzuki; Tadayuki Oshima; Reiko Kunisaki; Takayuki Matsumoto; Hiroyuki Hanai; Ken Fukunaga; Naoki Yoshimura; Toshimi Chiba; Shinsuke Funakoshi; Nobuo Aoyama; Akira Andoh; Hiroshi Nakase; Yohei Mizuta; Ryoichi Suzuki; Taiji Akamatsu; Masahiro Iizuka; Toshifumi Ashida; Toshifumi Hibi
Journal:  Am J Gastroenterol       Date:  2009-09-01       Impact factor: 10.864

10.  Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease.

Authors:  Keiji Ozeki; Satoshi Tanida; Tsutomu Mizoshita; Hironobu Tsukamoto; Masahide Ebi; Yoshinori Mori; Hiromi Kataoka; Takeshi Kamiya; Takashi Joh
Journal:  Case Rep Gastroenterol       Date:  2012-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.